Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

被引:1
作者
Linde, Caroline [1 ]
Chien, Yu-Ting [1 ]
Chen, Zhiqian [1 ]
Mu, Qingxin [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家卫生研究院;
关键词
nanoparticles; triple negative breast cancer; PD-1/PD-L1; pathway; combination therapy; tumor microenvironment; CHEMOTHERAPY; PHARMACOKINETICS; IMMUNOTHERAPY;
D O I
10.3389/fonc.2024.1393492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer with triple-negative subtype (TNBC) presents significant challenges with limited treatment options and a poorer prognosis than others. While PD-1/PD-L1 checkpoint inhibitors have shown promise, their efficacy in TNBC remains constrained. In recent years, nanoparticle (NP) technologies offer a novel approach to enhance cancer therapy by optimizing the tumor microenvironment and augmenting chemo- and immunotherapy effects in various preclinical and clinical settings. This review discusses recent investigations in NP strategies for improving PD-1/PD-L1 blockade-based combination therapy for TNBC. Those include single or multi-therapeutic NPs designed to enhance immunogenicity of the tumor, induce immunogenic cell death, and target immunosuppressive elements within the tumor microenvironment. The investigations also include NPs co-loaded with PD-L1 inhibitors and other therapeutic agents, leveraging targeted delivery and synergistic effects to maximize efficacy while minimizing systemic toxicity. Overall, NP approaches represent a promising avenue for enhancing PD-1/PD-L1 checkpoint blockade-based combination therapy in TNBC and encourage further developmental studies.
引用
收藏
页数:7
相关论文
共 50 条
[41]   Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade [J].
Bai, Jie ;
Gao, Zhitao ;
Li, Xiang ;
Dong, Liang ;
Han, Weidong ;
Nie, Jing .
ONCOTARGET, 2017, 8 (66) :110693-110707
[42]   Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis [J].
Dai, Youran ;
Ruan, Tianyin ;
Yang, Wenhui ;
Liu, Shan ;
Chen, Jiahao ;
Fang, Yingying ;
Li, Qiushuang .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
[43]   Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy [J].
Wang, Yusha ;
Zhang, Lei ;
Bai, Yun ;
Wang, Li ;
Ma, Xuelei .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[44]   Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines [J].
Braeutigam, Karen ;
Kabore-Wolff, Elodie ;
Hussain, Ahmad Fawzi ;
Polack, Stephan ;
Rody, Achim ;
Hanker, Lars ;
Koester, Frank .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (10) :2923-2933
[45]   Harmonizing PD-L1 testing in metastatic triple negative breast cancer [J].
Giugliano, Federica ;
Antonarelli, Gabriele ;
Tarantino, Paolo ;
Cortes, Javier ;
Rugo, Hope S. ;
Curigliano, Giuseppe .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (03) :345-348
[46]   PD-1/PD-L1 inhibitor-based immunotherapy in locally advanced or metastatic triple-negative breast cancer: A meta-analysis [J].
Chen, Yonghui ;
Shi, Liji ;
Yin, Weihua ;
Xia, Hongmei ;
Lin, Canling .
ONCOLOGY LETTERS, 2025, 29 (01)
[47]   Enhanced systemic antitumor efficacy of PD-1/PD-L1 blockade with immunological response induced by photodynamic therapy [J].
Sonokawa, Takumi ;
Fujiwara, Yukio ;
Pan, Cheng ;
Komohara, Yoshihiro ;
Usuda, Jitsuo .
THORACIC CANCER, 2024, 15 (18) :1429-1436
[48]   MHC Class I Loss in Triple-negative Breast Cancer A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors [J].
Dusenbery, Anna C. ;
Maniaci, Joseph L. ;
Hillerson, Natalie D. ;
Dill, Erik A. ;
Bullock, Timothy N. ;
Mills, Anne M. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (05) :701-707
[49]   A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism [J].
Zhu, Wang-Yu ;
Jin, Xiao-Yan .
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (09) :10075-10082
[50]   Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer [J].
Huang, Haozhe .
BIOINFORMATICS AND BIOMEDICAL ENGINEERING, PT II, IWBBIO 2024, 2024, 14849 :55-69